HalioDx is an immuno-oncology diagnostic company providing oncologists and Biopharma with first-in-class immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.
Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially organised tissue molecular information.
Immunoscore® is available Internationally as a CLIA or CE marked test to guide day to day oncologists’ decisions. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression.
HalioDx has an experienced team of more than 165 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies.
HalioDx headquarters and research laboratories are located in the heart of Marseille Immunopôle - Luminy, near research institutions and platforms in immunology, research centers and oncology care, and numerous biotechnology companies.
To better guide cancer therapies prescription and facilitate the development and registration of next generation immunotherapies, HalioDx is committed to provide reliable information to guide day to day oncologists’ decisions and to help drug developper in their clinical trials.
For these projects, HalioDx bring its expertise in immuno-oncology biomarkers and diagnostics development, notably with its proprietary assays Immunoscore®, Immunogram®, Immunosign® but also with undisclosed other proprietary biomarker approaches.
HalioDx is excited to be part of these ambitious projects gathering leading experts in selected and distinct cancers, as we are committed to demonstrate that our biomarker technology is broadly applicable in Immuno-oncology diagnostics. Indeed working in such a collaborative mode, on indications such as lung, colon and breast cancers, with the support of major medical experts is essential to drive medical innovation for patient’s care.
Better understand, predict and overcome anti-PD1/L1 resistance in lung cancer.
Stratify patients with specific type of colorectal cancer (microsatellite stable RAS mutant metastatic colorectal cancer or MSS RAS mt mCRC).
Impact of gut microbiome on response, resistance & toxicity to treatment in breast, lung, colon & skin cancers.